





APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
08/765,837	09/07/1999	RUTH LAUB	VANMA48.001A	6647	
75	90 03/25/2003				
	RTENS OLSON & E	EXAMINER			
SIXTEENTH F			NOLAN, PATRICK J		
NEWPORT BE	ACH, CA 92660		ART UNIT	PAPER NUMBER	
			1644		
			DATE MAILED: 03/25/2003	$\mathcal{A}$	

Please find below and/or attached an Office communication concerning this application or proceeding.

## Office Action Summary

Application No. 08/765,837 Applicant(s)

Examiner

Patrick J. Nolan

Art Unit 1644

The MAILING DATE of this communication appears on the cover sheet with the correspondence address							
	for Reply	_					
THE	ORTENED STATUTORY PERIOD FOR REPLY IS SET MAILING DATE OF THIS COMMUNICATION. ions of time may be available under the provisions of 37 CFR 1.136 (a). In						
mailing - If the p - If NO p - Failure - Any re	date of this communication.  Deriod for reply specified above is less than thirty (30) days, a reply within the period for reply is specified above, the maximum statutory period will apply a to reply within the set or extended period for reply will, by statute, cause the ply received by the Office later than three months after the mailing date of the patent term adjustment. See 37 CFR 1.704(b).	ne statutory minimum and will expire SIX (6) ne application to beco	of thirty (30 MONTHS f	0) days will be considered timely. rom the mailing date of this communication. DNED (35 U.S.C. § 133).			
Status							
1) 💢	Responsive to communication(s) filed on <u>Dec 30, 2</u>	2002		·			
2a) 💢	This action is <b>FINAL</b> . 2b) $\square$ This act	ion is non-fina					
3) 🗆	3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11; 453 O.G. 213.						
Disposi	tion of Claims						
4) 💢	Claim(s) 31-36 and 39-42			is/are pending in the application.			
4	a) Of the above, claim(s) 40-42			is/are withdrawn from consideration.			
_	Claim(s) 35						
6) 💢	Claim(s) 31-34, 36, and 39			is/are rejected.			
7) 🗆	Claim(s)						
8) 🗌	Claims	are	subject	to restriction and/or election requirement.			
Applica	tion Papers						
9) 🗆	The specification is objected to by the Examiner.						
10)□	)☐ The drawing(s) filed on is/are a)☐ accepted or b)☐ objected to by the Examiner.						
	Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
11)	The proposed drawing correction filed on	is	: a)□ a	approved b) $\square$ disapproved by the Examiner.			
	If approved, corrected drawings are required in reply t	to this Office ac	tion.				
12)	12) The oath or declaration is objected to by the Examiner.						
Priority under 35 U.S.C. §§ 119 and 120							
13) Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).							
a) [	a) All b) Some* c) None of:						
	1.  Certified copies of the priority documents have been received.						
	2. Certified copies of the priority documents have been received in Application No						
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).							
*See the attached detailed Office action for a list of the certified copies not received.							
14) Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).							
<ul> <li>a) ☐ The translation of the foreign language provisional application has been received.</li> <li>15) ☐ Acknowledgement is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.</li> </ul>							
Attachment(s)							
	tice of References Cited (PTO-892)	4) Interview Su	mmary (PTC	D-413) Paper No(s)			
_	tice of Draftsperson's Patent Drawing Review (PTO-948)	5) Notice of Inf	omal Paten	t Application (PTO-152)			
3)	3) Information Disclosure Statement(s) (PTO-1449) Paper No(s). 6) Other:						

Application/Control Number: 08/765,837

Art Unit: 1644

## **DETAILED ACTION**

1. This application is a national stage filing under U.S.C. 371 from PCT/BE95/00063, filed 7/14/95.

2. Claims 31-36 and 39-42 are pending.

Applicant's election without traverse of Group I, claims 31-36 and 39 in Paper No. 9, dated 11/27/00 is acknowledged. Claims 40-42 stand withdrawn from further consideration by the Examiner as being drawn to nonelected inventions (see 37 C.F.R. 1.142(b)).

- 3. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 C.F.R. 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a diligently-filed petition under 37 C.F.R. 1.48(b) and by the fee required under 37 C.F.R. 1.17(h).
- **4.** Claims 31-36 and 39 are presently under examination.

The following is a quotation of the appropriate paragraphs of 35 U.S.C. §102 that form the basis for the rejections under this section made in this Office action:

"A person shall be entitled to a patent unless --

- (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States."
- **5.** Claims 31-34, 36 and 39 stand rejected under 35 U.S.C. §102(b) as being anticipated by U.S. Patent No. 4,965,199, of record for reasons set forth in Paper No. 13.

Applicant's arguments filed 12-30-02 have been fully considered but are not found persuasive.

Applicant argues the '199 patent does not teach the recited fragments of Factor VIII.

However, the claims are not limited to the recited fragments. The word comprising opens the claim to read upon fragments of human Factor VIII polypeptide comprising the specific recited residues. The '199 patent teaches a fragment of human Factor VIII that comprises 7 residues contained between threonine 1739 and aspartic acid 1831, see column 39-40 in particular fragment 1799-1860, wherein said fragment contains a tyrosine or histidine residue, see amino acid residue 1815 in Figure 10. Furthermore, claim 36 is included because the '199 patent teaches the peptide fragment in complex form as a fusion protein and the phrase wherein said complex increases immunogenecity is non-limiting since it is not clear what the complex is more immunogenic than. Claim 39 is included since the '199 patent teaches pharmaceutical compositions of said fusion proteins. Claim 34 is included since the fragment taught by the '199 patent includes both SEQ ID NO. 5 and 6 in the fusion protein.

**6.** Applicant is notified that claim 35 is free of the prior art as of the last art search.

Application/Control Number: 08/765,837

Art Unit: 1644

7. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for response to this final action is set to expire THREE MONTHS from the date of this action. In the event a first response is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event will the statutory period for response expire later than SIX MONTHS from the date of this final action.

- **8.** Any inquiry concerning this communication or earlier communications from the examiner should be directed to Patrick Nolan whose telephone number is (703) 305-1987. The examiner can normally be reached on Monday through Friday from 8:30 am to 4:30 pm.
- **9.** If attempts to reach the examiner are unsuccessful, the examiner's supervisor, Christina Chan, can be reached at (703) 305-3973. The FAX number for our group, 1644, is (703) 305-7939. Any inquiry of a general nature relating to the status of this application or proceeding should be directed to the Group receptionist, whose telephone number is (703) 308-0196.

Patrick J. Nolan, Ph.D.

Primary Examiner, Group 1640

3/21/03